FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Vincent Miller

Research Profile

Disorders

Chemicals & Drugs

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Helena A Yu; Andreas Rimner; Naiyer A Rizvi; Camelia S Sima; Stephen B Solomon; Christopher G Azzoli; James Huang; Mark G Kris; Lee M Krug; Vincent A Miller; Paul Paik; Maria C Pietanza; Gregory J Riely
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Paul K Paik; Camelia S Sima; Daphne Ang; Sandra P D'Angelo; Snjezana Dogan; Melissa L Johnson; Mark G Kris; Marc Ladanyi; Vincent A Miller; Gregory J Riely
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Ken Takezawa; Valentina Pirazzoli; Katerina Politi; Gregory J Riely; Xiaoling Song; Paula J Spitzler; Maria E Arcila; Elisa de Stanchina; Yelena Y Janjigian; Mark G Kris; Marc Ladanyi; Mary Ann Melnick; Vincent A Miller; Caroline A Nebhan; Kadoaki Ohashi; William Pao
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Vincent Miller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Helena A Yu; Andreas Rimner; Naiyer A Rizvi; Camelia S Sima; Stephen B Solomon; Christopher G Azzoli; James Huang; Mark G Kris; Lee M Krug; Vincent A Miller; Paul Paik; Maria C Pietanza; Gregory J Riely
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(3):346-51.
2012: Paul K Paik; Camelia S Sima; Daphne Ang; Sandra P D'Angelo; Snjezana Dogan; Melissa L Johnson; Mark G Kris; Marc Ladanyi; Vincent A Miller; Gregory J Riely
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Cancer 2012;118(23):5840-7.
2012: Ken Takezawa; Valentina Pirazzoli; Katerina Politi; Gregory J Riely; Xiaoling Song; Paula J Spitzler; Maria E Arcila; Elisa de Stanchina; Yelena Y Janjigian; Mark G Kris; Marc Ladanyi; Mary Ann Melnick; Vincent A Miller; Caroline A Nebhan; Kadoaki Ohashi; William Pao
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Cancer discovery 2012;2(10):922-33.
2012: Pasi A Janne; Robert Kratzke; Marzia Capelletti; Jeffrey Crawford; Martin J Edelman; Lin Gu; Mark A Socinski; Thomas E Stinchcombe; Miguel A Villalona-Calero; Everett E Vokes; Xiaofei Wang; Vincent A Miller
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2063-9.
2012: Geoffrey R Oxnard; William Pao; Mark E Robson; Christopher G Azzoli; Marc Ladanyi; Vincent A Miller; Maria E Arcila
Screening for germline EGFR T790M mutations through lung cancer genotyping.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(6):1049-52.
2012: Maria C Pietanza; Katharine A Price; Gregory J Riely; Kendrith M Rowland; Ravi Salgia; Margaret Tonda; Michael S Wertheim; Christopher G Azzoli; Jan H Beumer; Afshin Dowlati; Shirish M Gadgeel; Mark G Kris; Lee M Krug; Thomas J Lynch; Vincent A Miller; Ben Mitchell; Naiyer A Rizvi
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(5):856-65.
2012: Vincent A Miller; Keunchil Park; Mehdi Shahidi; Wu-Chou Su; Yan Sun; Eng Huat Tan; Mengzhao Wang; Jacques Cadranel; Tsu-Yi Chao; Yuh-Min Chen; Xiuyu Julie Cong; Lucio Crino; Dae Seog Heo; Vera Hirsh; Sang-We Kim; Robert M Lorence; Caicun Zhou; James Chih-Hsin Yang
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
The lancet oncology 2012;13(5):528-38.
2012: Mai He; Pasi A Janne; Mark G Kris; Marc Ladanyi; Vincent A Miller; Khedoudja Nafa; Maria E Arcila; Marzia Capelletti; Michael J Eck; Michelle S Ginsberg; Cai-Hong Yun; Binsheng Zhao; Geoffrey R Oxnard
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1790-7.
2012: Maria C Pietanza; Nandagopal Vrindavanam; Heather A Wakelee; Ronald H Yanagihara; John Cho; Naveed Mahfooz Chowhan; Roel Funke; Shirish M Gadgeel; Primo Lara; Thomas James Lynch; Ben Mitchell; Nathan A Pennell; Vincent A Miller
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(1):219-26.
2011: Christian Grommes; Andrei I Holodny; Mark G Kris; Vincent A Miller; Geoffrey R Oxnard; William Pao; Jennifer L Clarke; Andrew B Lassman
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Neuro-oncology 2011;13(12):1364-9.
2011: Paul K Paik; Gregory J Riely; Camelia S Sima; Christopher G Azzoli; Robert T Heelan; Leonard P James; Mark G Kris; Vincent A Miller; Erin Moore; Kenneth K Ng; Naiyer A Rizvi
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.
Cancer chemotherapy and pharmacology 2011;68(5):1331-7.
2011: Gregory J Riely; Naiyer A Rizvi; Christopher G Azzoli; Melissa L Johnson; Mark G Kris; Lee M Krug; Chanoa Medina; Vincent A Miller; William Pao; Maria C Pietanza; Michelle S Ginsberg
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(8):1435-7.
2011: Juliann Chmielecki; Elisa de Stanchina; Jasmine Foo; Michelle S Ginsberg; Katherine Hutchinson; Akira Inoue; Mark G Kris; Marc Ladanyi; Franziska Michor; Vincent A Miller; Kadoaki Ohashi; Geoffrey R Oxnard; Nicholas D Socci; Romel Somwar; Martin L Sos; Roman K Thomas; Agnes Viale; Lu Wang; Katherine R Amato; Maria Arcila; William Pao
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Science translational medicine 2011;3(90):90ra59.
2011: Melissa L Johnson; Gregory J Riely; Naiyer A Rizvi; Christopher G Azzoli; Mark G Kris; Camelia S Sima; Michelle S Ginsberg; William Pao; Vincent A Miller
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(6):1128-31.
2011: Paul K Paik; Maria E Arcila; Michael Fara; Camelia S Sima; Vincent A Miller; Mark G Kris; Marc Ladanyi; Gregory J Riely
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2046-51.
2011: Sandra P D'Angelo; Maria C Pietanza; Melissa L Johnson; Gregory J Riely; Vincent A Miller; Camelia S Sima; Maureen F Zakowski; Valerie W Rusch; Marc Ladanyi; Mark G Kris
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2066-70.
2011: Trever G Bivona; Haley Hieronymus; Joel Parker; Kenneth Chang; Miquel Taron; Rafael Rosell; Philicia Moonsamy; Kimberly Dahlman; Vincent A Miller; Carlota Costa; Gregory Hannon; Charles L Sawyers
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Nature 2011;471(7339):523-6.
2010: Katharine A Price; Christopher G Azzoli; Lee M Krug; Maria C Pietanza; Naiyer A Rizvi; William Pao; Mark G Kris; Gregory J Riely; Robert T Heelan; Maria E Arcila; Vincent A Miller
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(10):1623-9.
2010: Jennifer L Clarke; William Pao; Nian Wu; Vincent A Miller; Andrew B Lassman
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Journal of neuro-oncology 2010;99(2):283-6.
2010: Natasha B Leighl; Luis E Raez; Benjamin Besse; Peter J Rosen; Fabrice Barlesi; E Massarelli; Nashat Gabrail; Lowell L Hart; Kathy S Albain; Lloyd Berkowitz; Ostap Melnyk; Frances A Shepherd; Lars Sternas; Judie Ackerman; Zhenming Shun; Vincent A Miller; Roy S Herbst
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(7):1054-9.
2010: Lecia V Sequist; Benjamin Besse; Thomas J Lynch; Vincent A Miller; Kwok K Wong; Barbara Gitlitz; Keith Eaton; Charles Zacharchuk; Amy Freyman; Christine Powell; Revathi Ananthakrishnan; Susan Quinn; Jean-Charles Soria
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):3076-83.
2010: Geoffrey R Oxnard; Vincent A Miller
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Oncology (Williston Park, N.Y.) 2010;24(5):392-9.
2010: Eric Haura; Alejandro D Ricart; Timothy G Larson; Philip J Stella; Lyudmila Bazhenova; Vincent A Miller; Roger B Cohen; Peter D Eisenberg; Paulina Selaru; Keith D Wilner; Shirish M Gadgeel
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(8):2450-7.
2010: Yelena Janjigian; Wooin Lee; Mark G Kris; Vincent A Miller; Lee M Krug; Christopher G Azzoli; Emir Senturk; M Wade Calcutt; Naiyer A Rizvi
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Cancer chemotherapy and pharmacology 2010;65(5):833-8.
2010: Nicolas Girard; Emil Lou; Christopher G Azzoli; Rekha Reddy; Mark Robson; Megan Harlan; Irene Orlow; Yasushi Yatabe; Khedoudja Nafa; Marc Ladanyi; Agnes Viale; Mark G Kris; Gregory J Riely; Vincent A Miller; Robert J. Klein; Keitaro Matsuo; William Pao
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):755-63.
2010: David Jackman; William Pao; Gregory J Riely; Jeffrey A Engelman; Mark G Kris; Pasi A Janne; Thomas Lynch; Bruce E Johnson; Vincent A Miller
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):357-60.
2009: David M Jackman; Vincent A Miller; Leigh-Anne Cioffredi; Beow Y Yeap; Pasi A Janne; Gregory J Riely; Marielle Gallegos Ruiz; Giuseppe Giaccone; Lecia V Sequist; Bruce E Johnson
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5267-73.
2009: Maureen F Zakowski; Sanaa Hussain; William Pao; Marc Ladanyi; Michelle S Ginsberg; Robert T Heelan; Vincent A Miller; Valerie W Rusch; Mark G Kris
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Archives of pathology & laboratory medicine 2009;133(3):470-7.
2009: Ilya Glezerman; Mark G Kris; Vincent A Miller; Surya V Seshan; Carlos D Flombaum
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Clinical nephrology 2009;71(2):130-9.
2009: Gregory J Riely; Naiyer A Rizvi; Mark G Kris; Daniel T Milton; David B Solit; Neal Rosen; Emir Senturk; Christopher G Azzoli; Julie R Brahmer; Francis M Sirotnak; Venkatraman E Seshan; Margaret Fogle; Michelle Ginsberg; Vincent A Miller; Charles Rudin
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
2008: James Bean; Gregory J Riely; Marissa Balak; Jenifer L Marks; Marc Ladanyi; Vincent A Miller; William Pao
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7519-25.
2008: Gregory J Riely; Mark G Kris; Daniel Rosenbaum; Jenifer Marks; Allan Li; Dhananjay A Chitale; Khedoudja Nafa; Elyn Riedel; Meier Hsu; William Pao; Vincent A Miller; Marc Ladanyi
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5731-4.
2008: Jenifer L Marks; Ben Golas; Tomas Kirchoff; Vincent A Miller; Gregory J Riely; Kenneth Offit; William Pao
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(7):805.
2008: Allan R Li; Dhananjay Chitale; Gregory J Riely; William Pao; Vincent A Miller; Maureen F Zakowski; Valerie W Rusch; Mark G Kris; Marc Ladanyi
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
The Journal of molecular diagnostics : JMD 2008;10(3):242-8.
2008: Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1472-8.
2008: Naiyer A Rizvi; Gregory J Riely; Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; John Fiore; Gloria Chia; Martin Brower; Robert T Heelan; Michael J Hawkins; Mark G Kris
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):639-43.
2008: Vincent A Miller
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Seminars in oncology nursing 2008;24(1):27-33.
2008: Yelena Janjigian; Vincent A Miller
Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?
Nature clinical practice. Oncology 2008;5(1):10-1.
2007: James Bean; Cameron Brennan; Jin-Yuan Shih; Gregory J Riely; Agnes Viale; Lu Wang; Dhananjay Chitale; Noriko Motoi; Janos Szoke; Stephen Broderick; Marissa N Balak; Wen-Cheng Chang; Chong-Jen Yu; Adi F Gazdar; Harvey I Pass; Valerie W Rusch; William Gerald; Shiu-Feng Huang; Pan-Chyr Yang; Vincent A Miller; Marc Ladanyi; Chih-Hsin Yang; William Pao
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(52):20932-7.
2007: Barbara L Lytle; Elizabeth S Fraulo; Jyotsna Mulgund; Vincent A Miller; Matthew T Roe; Sidney C Smith; W Brian Gibler; Erik Ohman; eric peterson
What aspects of hospital culture influence quality?
Critical pathways in cardiology 2007;6(4):145-9.
2007: Roy S Herbst; Angela M Davies; Ronald B Natale; Thao P Dang; Joan H Schiller; Linda L Garland; Vincent A Miller; David S Mendelson; Annick D Van den Abbeele; Yulia Melenevsky; Daniel J de Vries; David A Eberhard; Benjamin Lyons; Stuart G Lutzker; Bruce E Johnson
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6175-81.
2007: Vincent Liu; Dorothy A White; Maureen F Zakowski; William D Travis; Mark G Kris; Michelle S Ginsberg; Vincent A Miller; Christopher G Azzoli
Pulmonary toxicity associated with erlotinib.
Chest 2007;132(3):1042-4.
2007: Gregory J Riely; Mark G Kris; Binsheng Zhao; Timothy Akhurst; Daniel T Milton; Erin Moore; Leslie Tyson; William Pao; Naiyer A Rizvi; Lawrence H Schwartz; Vincent A Miller
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):5150-5.
2007: Gregory J Riely; Vincent A Miller
Vascular endothelial growth factor trap in non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4623-7.
2007: Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Cancer 2007;110(3):599-605.
2007: Christopher G Azzoli; Lee M Krug; Vincent A Miller; Naiyer A Rizvi; Mark G Kris; Megan Dunne; Amy Farmer; Barbara Pizzo; Leslie Tyson; Teresa Seeger; Barbara Coleman; Erin Moore; Lauren Lastinger; Venkatraman E Seshan; Charles Rudin
A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(7):638-44.
2007: Christopher G Azzoli; Lee M Krug; Jorge Gomez; Vincent A Miller; Mark G Kris; Michelle S Ginsberg; Roxanne Henry; Jessica Jones; Leslie Tyson; Megan Dunne; Barbara Pizzo; Amy Farmer; Venkatraman E Seshan; Robert Steffen; Francis M Sirotnak
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2692-8.
2007: Matthew G Fury; David B Solit; Yungpo Bernard Su; Neal Rosen; Francis M Sirotnak; Robert P Smith; Christopher G Azzoli; Jorge Gomez; Vincent A Miller; Mark G Kris; Barbara A Pizzo; Roxanne Henry; David G Pfister; Naiyer A Rizvi
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2007;59(4):467-75.
2006: Gregory J Riely; Katerina Politi; Vincent A Miller; William Pao
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7232-41.
2006: Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6494-501.
2006: Daniel T Milton; Gregory J Riely; William Pao; Vincent A Miller; Mark G Kris; Robert T Heelan
Molecular on/off switch.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4940-2.
2006: Arti Hurria; Mark T Fleming; Sharyn D Baker; W Kevin Kelly; Katie Cutchall; Katherine S Panageas; James Caravelli; Henry Yeung; Mark G Kris; Jorge Gomez; Vincent A Miller; Gabriella D'Andrea-Carlino; Howard I Scher; Larry Norton; Clifford Hudis
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6100-5.
2006: Daniel T Milton; Christopher G Azzoli; Robert T Heelan; Venkatraman E Seshan; Jorge Gomez; Mark G Kris; Lee M Krug; William Pao; Naiyer A Rizvi; Megan Dunne; Vincent A Miller
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Cancer 2006;107(5):1034-41.
2006: Duykhanh Pham; Mark G Kris; Gregory J Riely; Inderpal S Sarkaria; Tiffani McDonough; Shaokun Chuai; Venkatraman E Seshan; Vincent A Miller; Marc Ladanyi; William Pao; Richard K Wilson; Bhuvanesh Singh; Valerie W Rusch
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(11):1700-4.
2006: Vincent A Miller
Optimizing therapy in previously treated non-small cell lung cancer.
Seminars in oncology 2006;33(1 Suppl 1):S25-31.
2006: Gregory J Riely; William Pao; Duykhanh Pham; Allan R Li; Naiyer A Rizvi; Venkatraman E Seshan; Maureen F Zakowski; Mark G Kris; Marc Ladanyi; Vincent A Miller
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):839-44.
2005: Lee M Krug; Vincent A Miller; Jyoti Patel; John P Crapanzano; Christopher G Azzoli; Jorge Gomez; Mark G Kris; Robert T Heelan; Barbara Pizzo; Leslie Tyson; Christine Sheehan; Jeffrey S Ross; Venkatraman E Seshan
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Cancer 2005;104(10):2149-55.
2005: William Pao; Marc Ladanyi; Vincent A Miller
Erlotinib in lung cancer.
The New England journal of medicine 2005;353(16):1739-41; author reply 1739-41.
2005: Roy S Herbst; Diane Prager; Robert Hermann; Louis Fehrenbacher; Bruce E Johnson; Alan B Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David A Ramies; David H Johnson; Vincent A Miller
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5892-9.
2005: David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Janne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5900-9.
2005: Daniel T Milton; Vincent A Miller
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer.
Seminars in oncology 2005;32(3):299-314.
2005: Antonio M P Omuro; Mark G Kris; Vincent A Miller; Enrico Franceschi; Neelam Shah; Daniel T Milton; Lauren E Abrey
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Cancer 2005;103(11):2344-8.
2005: Lee M Krug; John P Crapanzano; Christopher G Azzoli; Vincent A Miller; Naiyer A Rizvi; Jorge Gomez; Mark G Kris; Barbara Pizzo; Leslie Tyson; Megan Dunne; Robert T Heelan
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Cancer 2005;103(10):2128-31.
2005: Vincent A Miller; Fred R Hirsch; David H Johnson
Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(14):3288-93.
2005: William Pao; Vincent A Miller
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2556-68.
2005: William Pao; Vincent A Miller; Katerina Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS medicine 2005;2(3):e73.
2005: William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold Varmus
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PLoS medicine 2005;2(1):e17.
2005: Neelam T Shah; Mark G Kris; William Pao; Leslie Tyson; Barbara Pizzo; Murk-Hein Heinemann; Leah Ben-Porat; Dana L Sachs; Robert T Heelan; Vincent A Miller
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):165-74.
2005: Scott A Laurie; Vincent A Miller; Stefan C Grant; Mark G Kris; Kenneth K Ng
Phase I study of green tea extract in patients with advanced lung cancer.
Cancer chemotherapy and pharmacology 2005;55(1):33-8.
2004: Inderpal S Sarkaria; Duykhanh Pham; Ronald A Ghossein; Simon G Talbot; Michael Hezel; Maria E Dudas; Michael I Ebright; Shaokun Chuai; Natalie Memoli; Venkatraman E Seshan; Vincent A Miller; Mark G Kris; Maureen F Zakowski; Valerie W Rusch; Bhuvanesh Singh
SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2004;78(5):1734-41.
2004: Lee M Krug; Govind Ragupathi; Chandra Hood; Mark G Kris; Vincent A Miller; Jennifer R Allen; Stacy J Keding; Samuel J Danishefsky; Jorge Gomez; Leslie Tyson; Barbara Pizzo; Valerie Baez; Philip O Livingston
Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6094-100.
2004: William Pao; Vincent A Miller; Maureen F Zakowski; Jennifer Doherty; Katerina Politi; Inderpal S Sarkaria; Bhuvanesh Singh; Robert T Heelan; Valerie W Rusch; Lucinda Fulton; Elaine R Mardis; Doris Kupfer; Richard Wilson; Mark G Kris; Harold Varmus
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(36):13306-11.
2004: William Pao; Vincent A Miller; Venkatraman E Seshan; Mark G Kris
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Journal of the National Cancer Institute 2004;96(15):1117-9.
2004: Eric Sherman; David M Rubin; Venkatraman E Seshan; Gary K Schwartz; Vincent A Miller; Mark Radzyner; Hirsch S Ruchlin; David Spriggs; David G Pfister
Using patients as their own controls for cost evaluation of phase I clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1308-14.
2004: Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher G Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer A Rizvi; Barbara Pizzo; Leslie Tyson; Venkatraman E Seshan; Leah Ben-Porat; Natalie Memoli; Maureen F Zakowski; Valerie W Rusch; Robert T Heelan
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1103-9.
2004: Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent A Miller; Christian Manegold; Giorgio V Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):785-94.
2004: Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio V Scagliotti; Rafael Rosell; Vincent A Miller; Ronald B Natale; Joan H Schiller; Joachim von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):777-84.
2004: Lee M Krug; Govind Ragupathi; Kenneth K Ng; Chandra Hood; Harold J Jennings; Zhongwu Guo; Mark G Kris; Vincent A Miller; Barbara Pizzo; Leslie Tyson; Valerie Baez; Philip O Livingston
Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):916-23.
2004: William Pao; Vincent A Miller; Mark G Kris
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Seminars in cancer biology 2004;14(1):33-40.
2003: Neelam T Shah; Vincent A Miller
Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Clinical lung cancer 2003;5(3):182-6.
2003: Yuhong She; Fei Lee; Jing Chen; Adriana Haimovitz-Friedman; Vincent A Miller; Valerie R Rusch; Mark G Kris; Francis M Sirotnak
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3773-8.
2003: Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; Lee M Krug; Martee Hensley; Eileen O'Reilly; Raymond J Muller; Mark G Kris
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.
American journal of clinical oncology 2003;26(3):247-51.
2003: Lee M Krug; Christopher G Azzoli; Mark G Kris; Vincent A Miller; Nushmia Z Khokhar; William Tong; Michelle S Ginsberg; Venkatraman E Seshan; Leslie Tyson; Barbara Pizzo; Valerie Baez; Kenneth K Ng; Francis M Sirotnak
10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2072-8.
2003: Vincent A Miller; David H Johnson; Lee M Krug; Barbara Pizzo; Leslie Tyson; Wendy Perez; Peggy Krozely; Alan B Sandler; David Carbone; Robert T Heelan; Mark G Kris; Robert Smith; Judith Ochs
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2094-100.
2003: Christopher G Azzoli; Vincent A Miller; Kenneth K Ng; Lee M Krug; David Spriggs; William P Tong; Elyn Riedel; Mark G Kris
A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2003;51(6):493-8.
2003: Jyoti D Patel; Lee M Krug; Christopher G Azzoli; Jorge Gomez; Mark G Kris; Vincent A Miller
Targeting lethal minimal residual disease in small cell lung cancer.
Seminars in oncology 2003;30(1):79-85.
2003: Lee M Krug; Vincent A Miller; Daniel A Filippa; Venkatraman E Seshan; Kenneth K Ng; Mark G Kris
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine.
Lung cancer (Amsterdam, Netherlands) 2003;39(2):139-43.
2002: Michael I Ebright; Maureen F Zakowski; Jocelyne Martin; Venkatraman E Seshan; Vincent A Miller; Manjit S Bains; Robert J Downey; Robert J Korst; Mark G Kris; Valerie W Rusch
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.
The Annals of thoracic surgery 2002;74(5):1640-6; discussion 1646-7.
2002: Robert J Downey; Kenneth K Ng; Mark G Kris; Manjit S Bains; Vincent A Miller; Robert T Heelan; Mark H Bilsky; Robert J Ginsberg; Valerie W Rusch
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis.
Lung cancer (Amsterdam, Netherlands) 2002;38(2):193-7.
2002: Carol Aghajanian; Steven L Soignet; Don S Dizon; Christine S Pien; Julian Adams; Peter J Elliott; Paul Sabbatini; Vincent A Miller; Martee Hensley; Sandra Pezzulli; Christina Canales; Adil Daud; David Spriggs
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2505-11.
2002: Scott A Laurie; Mark G Kris; Carol S Portlock; Kenneth E Rosenzweig; Vincent A Miller; Lee M Krug; Valerie W Rusch
The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease.
Cancer 2002;95(1):119-26.
2002: Christopher G Azzoli; Lee M Krug; Vincent A Miller; Mark G Kris; Robert Mass
Trastuzumab in the treatment of non-small cell lung cancer.
Seminars in oncology 2002;29(1 Suppl 4):59-65.
2001: V Georgoulias; G Scagliotti; Vincent A Miller; J Eckardt; J Y Douillard; C Manegold
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Seminars in oncology 2001;28(1 Suppl 2):15-21.
2000: Francis M Sirotnak; Maureen F Zakowski; Vincent A Miller; Howard I Scher; Mark G Kris
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4885-92.
2000: Francis M Sirotnak; Hans-Guido Wendel; William G Bornmann; William P Tong; Vincent A Miller; Howard I Scher; Mark G Kris
Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3705-12.
2000: Lee M Krug; Kenneth K Ng; Mark G Kris; Vincent A Miller; William Tong; Robert T Heelan; L Leon; D Leung; J Kelly; Stefan C Grant; Francis M Sirotnak
Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3493-8.
2000: Frank V Fossella; Russell F DeVore; R N Kerr; Jeffrey Crawford; R R Natale; F Dunphy; L Kalman; Vincent A Miller; Jin S Lee; M Moore; David R Gandara; D Karp; Everett E Vokes; Mark G Kris; Y Kim; F Gamza; Luz D Hammershaimb
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2354-62.
2000: Steven L Soignet; Vincent A Miller; David G Pfister; B J Bienvenu; R Ho; B A Parker; S A Amyotte; A Cato; RP Warrell
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550).
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1731-5.
2000: Vincent A Miller
Trials of vinorelbine and docetaxel in the treatment of advanced non small-cell lung cancer.
Clinical lung cancer 2000;1 Suppl 1():S24-6.
2000: Vincent A Miller; Mark G Kris
Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Seminars in oncology 2000;27(2 Suppl 3):3-10.
2000: Vincent A Miller; Lee M Krug; Kenneth K Ng; Barbara Pizzo; Wendy Perez; Robert T Heelan; Mark G Kris
Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1346-50.
2000: Vincent A Miller; Kenneth K Ng; Lee M Krug; Wendy Perez; Barbara Pizzo; Robert T Heelan; Mark G Kris
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Cancer 2000;88(5):1045-50.
2000: Lee M Krug; Vincent A Miller; Gregory P Kalemkerian; M J Kraut; Kenneth K Ng; Robert T Heelan; Barbara A Pizzo; Wendy Perez; N McClean; Mark G Kris
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):227-8.
2000: Ari D Brooks; W Tong; FM Benedetti; Y Kaneda; Vincent A Miller; RP Warrell
Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery.
Cancer chemotherapy and pharmacology 2000;46(4):313-8.
1999: Lee M Krug; Vincent A Miller
Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
Seminars in oncology 1999;26(5 Suppl 16):24-6; discussion 41-2.
1999: Lee M Krug; Stefan C Grant; Vincent A Miller; Kenneth K Ng; Mark G Kris
Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
Seminars in oncology 1999;26(5 Suppl 15):55-61.
1999: Maura Dickler; Govind Ragupathi; Nancy X Liu; Cristina Musselli; D J Martino; Vincent A Miller; Mark G Kris; F T Brezicka; Philip O Livingston; Stefan C Grant
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2773-9.
1999: Kenneth K Ng; Mark G Kris; Robert J Ginsberg; Robert T Heelan; Katherine M W Pisters; Vincent A Miller; Stefan C Grant; Manjit S Bains; Valerie W Rusch; Kenneth E Rosenzweig; N Martini
Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma.
Cancer 1999;86(7):1189-97.
1999: Vincent A Miller
Docetaxel (Taxotere) in combination with vinorelbine in non-small cell lung cancer.
Seminars in oncology 1999;26(3 Suppl 10):12-4.
1999: JR Rigas; Mark G Kris; Vincent A Miller; Katherine M W Pisters; Robert T Heelan; Stefan C Grant; DW Fennelly; T C Chou; Francis M Sirotnak
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):601-3.
1999: Barbara A Pizzo; Katherine M W Pisters; Vincent A Miller; Stefan C Grant; L Baltzer; L Hinckley; Mark G Kris
Oral cisapride for the control of delayed vomiting following high-dose cisplatin.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999;7(1):44-6.
1998: Nicholas J Vander Els; Vincent A Miller
Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.
Chest 1998;114(6):1779-81.
1998: Hedy L Kindler; Mark G Kris; I E Smith; Vincent A Miller; Stefan C Grant; J B Krebs; G A Ross; M L Slevin
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
American journal of clinical oncology 1998;21(5):438-41.
1998: Vincent A Miller
Docetaxel in the management of advanced non-small cell lung cancer.
Seminars in oncology 1998;25(3 Suppl 8):15-9.
1998: Ulrich Gatzemeier; G Rodriguez; J Treat; Vincent A Miller; R von Roemeling; J Viallet; A Rey
Tirapazamine-cisplatin: the synergy.
British journal of cancer 1998;77 Suppl 4():15-7.
1997: Vincent A Miller; Kenneth K Ng; Stefan C Grant; Hedy L Kindler; Barbara Pizzo; Robert T Heelan; R von Roemeling; Mark G Kris
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1269-71.
1997: Vincent A Miller
Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial.
Seminars in oncology 1997;24(4 Suppl 14):S14-15-S14-17.
1997: Mark G Kris; Vincent A Miller; Kenneth K Ng; Stefan C Grant
The development of docetaxel (Taxotere) in non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 14):S14-1-S14-4.
1997: Vincent A Miller; FM Benedetti; JR Rigas; A L Verret; David G Pfister; David J Straus; Mark G Kris; M Crisp; R Heyman; GR Loewen; JA Truglia; RP Warrell
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):790-5.
1997: Vincent A Miller; JR Rigas; William P Tong; J R Reid; Katherine M W Pisters; Stefan C Grant; Robert T Heelan; Mark G Kris
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(5):415-8.
1996: Katherine M W Pisters; L B Tyson; William Tong; Martin Fleisher; Vincent A Miller; Stefan C Grant; David G Pfister; J R Rigas; C L Densmore; G Krol; Robert T Heelan; Francis M Sirotnak; Joseph R Bertino; Mark G Kris
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(11):1819-24.
1996: J R Rigas; Vincent A Miller; Zuo-Feng Zhang; David S Klimstra; William P Tong; Mark G Kris; RP Warrell
Metabolic phenotypes of retinoic acid and the risk of lung cancer.
Cancer research 1996;56(12):2692-6.
1996: Vincent A Miller; J R Rigas; F M Benedetti; A L Verret; William P Tong; Mark G Kris; G M Gill; GR Loewen; JA Truglia; E H Ulm; RP Warrell
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):471-5.
1995: Vincent A Miller; J R Rigas; Katherine M W Pisters; Stefan C Grant; David G Pfister; Robert T Heelan; Mark G Kris
Ifosfamide plus high-dose cisplatin in patients with non-small cell lung cancer previously treated with chemotherapy.
American journal of clinical oncology 1995;18(4):303-6.
1995: Vincent A Miller; Victor E Reuter; Howard I Scher
Primary squamous cell carcinoma of the prostate after radiation seed implantation for adenocarcinoma.
Urology 1995;46(1):111-3.
1995: Vincent A Miller; J R Rigas; Stefan C Grant; Katherine M W Pisters; Mark G Kris
New chemotherapeutic agents for non-small cell lung cancer.
Chest 1995;107(6 Suppl):306S-311S.
1995: W H Miller; Ann Jakubowski; William P Tong; Vincent A Miller; J R Rigas; F Benedetti; G M Gill; JA Truglia; E Ulm; M Shirley
9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia.
Blood 1995;85(11):3021-7.
1995: Mark G Kris; Katherine M W Pisters; Robert J Ginsberg; J R Rigas; Vincent A Miller; Stefan C Grant; R J Gralla; Robert T Heelan; N Martini
Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2).
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S47-57.
1995: P A Francis; Mark G Kris; J R Rigas; Stefan C Grant; Vincent A Miller
Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
Lung cancer (Amsterdam, Netherlands) 1995;12 Suppl 1():S163-72.
1995: Vincent A Miller; J R Rigas; P A Francis; Stefan C Grant; Katherine M W Pisters; Venkatraman E Seshan; K Woolley; Robert T Heelan; Mark G Kris
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.
Cancer 1995;75(4):968-72.
1995: J R Rigas; P A Francis; Vincent A Miller; William P Tong; Nancy Roistacher; Mark G Kris; J P Orazem; C W Young; RP Warrell
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
Cancer chemotherapy and pharmacology 1995;35(6):483-8.
1994: Vincent A Miller; J R Rigas; J R Muindi; William P Tong; Venkatraman E Seshan; Mark G Kris; RP Warrell
Modulation of all-trans retinoic acid pharmacokinetics by liarozole.
Cancer chemotherapy and pharmacology 1994;34(6):522-6.